Foghorn Therapeutics (FHTX) to Release Earnings on Thursday

Foghorn Therapeutics (NASDAQ:FHTX) is projected to issue its quarterly earnings data before the market opens on Thursday, March 6th. Analysts expect the company to announce earnings of ($0.43) per share and revenue of $8.56 million for the quarter.

Foghorn Therapeutics Trading Down 10.9 %

NASDAQ:FHTX opened at $4.32 on Tuesday. The stock has a market capitalization of $240.24 million, a P/E ratio of -2.25 and a beta of 3.18. Foghorn Therapeutics has a 1 year low of $3.86 and a 1 year high of $10.25. The firm has a 50 day moving average of $4.75 and a 200-day moving average of $6.78.

Analyst Ratings Changes

Several analysts have recently commented on the company. B. Riley began coverage on Foghorn Therapeutics in a report on Thursday, January 30th. They set a “buy” rating and a $10.00 target price on the stock. HC Wainwright reiterated a “buy” rating and set a $13.00 price target (down previously from $20.00) on shares of Foghorn Therapeutics in a research report on Tuesday, December 17th. Finally, Jefferies Financial Group lowered their price objective on shares of Foghorn Therapeutics from $18.00 to $14.00 and set a “buy” rating for the company in a research report on Monday, December 16th. One investment analyst has rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Foghorn Therapeutics currently has a consensus rating of “Buy” and an average price target of $13.17.

Foghorn Therapeutics Company Profile

Foghorn Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.